» Articles » PMID: 33437682

Urgent Need to Improve Programmatic Management of Patients with HIV Failing First-line Antiretroviral Therapy

Overview
Date 2021 Jan 13
PMID 33437682
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Delayed identification and response to virologic failure in case of first-line antiretroviral therapy (ART) in resource-limited settings is a threat to the health of HIV-infected patients. There is a need for the implementation of an effective, standardized response pathway in the public sector.

Discussion: We evaluated published cohorts describing virologic failure on first-line ART. We focused on gaps in the detection and management of treatment failure, and posited ways to close these gaps, keeping in mind scalability and standardization. Specific shortcomings repeatedly recorded included early loss to follow-up (>20%) after recognized first-line ART virologic failure; frequent delays in confirmatory viral load testing; and excessive time between the confirmation of first-line ART failure and initiation of second-line ART, which exceeded 1 year in some cases. Strategies emphasizing patient tracing, resistance testing, drug concentration monitoring, adherence interventions, and streamlined response pathways for those failing therapy are further discussed.

Conclusion: Comprehensive, evidence-based, clinical operational plans must be devised based on findings from existing research and further tested through implementation science research. Until this standard of evidence is available and implemented, high rates of losses from delays in appropriate switch to second-line ART will remain unacceptably common and a threat to the success of global HIV treatment programs.

Citing Articles

Dolutegravir Resistance in African Programmatic Settings Among Patients With Failure of Dolutegravir-based ART.

Murphy R, Bedesi P, Perumal N, Gosnell B, Hatlen T, Brijkumar J Open Forum Infect Dis. 2024; 11(7):ofae321.

PMID: 38947737 PMC: 11214099. DOI: 10.1093/ofid/ofae321.


Exploring barriers to switching "on time" to second-line antiretroviral therapy among nurses in primary health care facilities, Ekurhuleni Health District, South Africa.

Tenza I, Njuguna C, Sodo P, Ruch A, Francis J, Omole O PLoS One. 2023; 18(4):e0284996.

PMID: 37099552 PMC: 10132530. DOI: 10.1371/journal.pone.0284996.

References
1.
Sunpath H, Hatlen T, Naidu K, Msimango P, Adams R, Moosa M . Targeting the third '90': introducing the viral load champion. Public Health Action. 2019; 8(4):225-231. PMC: 6361489. DOI: 10.5588/pha.18.0063. View

2.
Geng E, Emenyonu N, Bwana M, Glidden D, Martin J . Sampling-based approach to determining outcomes of patients lost to follow-up in antiretroviral therapy scale-up programs in Africa. JAMA. 2008; 300(5):506-7. PMC: 3711416. DOI: 10.1001/jama.300.5.506. View

3.
Bvochora T, Satyanarayana S, Takarinda K, Bara H, Chonzi P, Komtenza B . Enhanced adherence counselling and viral load suppression in HIV seropositive patients with an initial high viral load in Harare, Zimbabwe: Operational issues. PLoS One. 2019; 14(2):e0211326. PMC: 6363281. DOI: 10.1371/journal.pone.0211326. View

4.
Havlir D, Lockman S, Ayles H, Larmarange J, Chamie G, Gaolathe T . What do the Universal Test and Treat trials tell us about the path to HIV epidemic control?. J Int AIDS Soc. 2020; 23(2):e25455. PMC: 7038879. DOI: 10.1002/jia2.25455. View

5.
Jobanputra K, Parker L, Azih C, Okello V, Maphalala G, Kershberger B . Factors associated with virological failure and suppression after enhanced adherence counselling, in children, adolescents and adults on antiretroviral therapy for HIV in Swaziland. PLoS One. 2015; 10(2):e0116144. PMC: 4335028. DOI: 10.1371/journal.pone.0116144. View